Catalyst Event
Innovent Biologics Inc (1801) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
5/8/2026, 12:00:00 AM
The NMPA is expected to approve the Mazdutide pen for type 2 diabetes on May 8, 2026; this core product approval's medium market impact is expected
Korean Translation
2026년 5월 8일 중국 NMPA의 마즈두타이드 펜 승인이 예상되며, 핵심 제품 승인의 중간 정도 시장 영향력이 예상됨
Related Recent Events
JD Health International Inc (6618) · Earnings Release
Low importance estimated as no market reaction has occurred yet; Q2 2026 earnings report scheduled.
8/12/2026, 12:00:00 AM
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date on June 16, 2026, for the final dividend of RMB 1.43 per 10 shares, scheduled to be paid on July 13, 2026. Low importance estimated as the dividend amount is within historical norms, scheduled.
6/16/2026, 12:00:00 AM
Grand Pharmaceutical Group Ltd (512) · Other
Ex-dividend date (2026-06-12) for the proposed 2025 final dividend of HK$0.169 per share is scheduled.
6/12/2026, 12:00:00 AM
Veracyte Inc (VCYT) · Other
Annual Meeting of Stockholders on 2026-06-10, with proposals including the election of directors and an expansion of the 2023 Equity Incentive Plan scheduled.
6/10/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Pacific Biosciences of California Inc (PACB) · Other
The 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026, including a proposal to increase the number of shares reserved for the 2020 Equity Incentive Plan by 16,000,000. A low impact is estimated due to potential share dilution, scheduled.
6/3/2026, 12:00:00 AM